Genomic Health sales and marketing update

Genomic Health said Medicare administrative contractor Palmetto GBA LLC (Columbia, S.C.) issued a local coverage determination (LCD) that covers the company’s Oncotype Dx prostate cancer assay for qualified patients. The LCD takes effect on Oct. 1. Palmetto will cover the test for prostate cancer patients who are defined as low- or very low-risk by National Comprehensive Cancer Network (NCCN) guidelines and who meet additional criteria to help identify patients who can be “conservatively managed” rather than treated with surgery or radiation therapy. ...